3 Results for "

ER-positive Breast Cancer Models

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "ER-positive Breast Cancer Models" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-125236
CAS No.: 1643947-30-1
Purity:  99.74%
Synonyms: BET-IN-19
Research Areas:  

Cancer

ZEN-3694 (BET-IN-19) is an orally active BET inhibitor. ZEN-3694 regulates the function of BET proteins, thereby downregulating pathways involved in cell cycle regulation, ER signaling, AR signaling, AR splice variants, MYC, GR, cell growth, inflammation, and cellular immune responses. ZEN-3694 inhibits proliferation, induces apoptosis, reverses the upregulation of CDK6 and CCND1, restores cell cycle arrest, and inhibits CDK6 via miR-34a-5p. ZEN-3694 can be used in research related to HER2 breast cancer and metastatic castration-resistant prostate cancer .
loading...
    loading...
Cat. No.: HY-148789
CAS No.: 2092925-89-6
Purity:  99.90%
Synonyms: OP-1250
Target:  

Estrogen Receptor/ERR

Research Areas:  

Inflammation/Immunology Cancer

Palazestrant is an antiestrogen and antineoplastic agent. Palazestrant can completely inhibit the activity of 17b-estradiol (E2) with IC50 value of 6.4 nM, and inhibit the proliferation of MCF7 and CAMA-1 cells with IC50 value of 1.4-1.6 nM. Palazestrant can inhibit ER +/HER2 + cancer .
loading...
    loading...
Cat. No.: HY-149480
CAS No.: 2832865-25-3
Purity:  98.72%
Research Areas:  

Cancer

ERD-3111 is an orally active PROTAC degrader targeting estrogen receptor α (ERα), with a DC50 of 0.5 nM. ERD-3111 induces ERα degradation in breast cancer cells, and triggers tumor regression or complete inhibition of tumor growth in ER-positive breast cancer xenograft models. ERD-3111 can be used in breast cancer-related research .
loading...
    loading...